Agios Pharmaceuticals, Inc. (AGIO) Stock

Agios Pharmaceuticals, Inc. (AGIO) is a Healthcare stock trading at $33.09 (as of 2026-08-21), with a market capitalization of $1.97B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Understand Agios Pharmaceuticals, Inc.: how it makes money

Agios Pharmaceuticals develops cellular-metabolism medicines, sells PYRUKYND for hemolytic anemias, and develops AG-946; it makes money primarily from PYRUKYND product sales.

The profit model depends on scaling sales of one approved medicine, PYRUKYND, while funding the development of additional therapies.

Business quality (Unprofitable): The company is unprofitable: gross margin 93% indicates strong product economics, but operating margin -247% shows that operating costs far exceed gross profit.

Bull case

Strong product economics support scale: PYRUKYND has a gross margin 93%, so additional product revenue could contribute meaningfully toward covering development and commercial costs if uptake expands.

Bear case

Operating costs overwhelm gross profit: The operating margin -247% shows that current operating expenses far exceed gross profit, so strong product-level economics have not yet produced a self-funding business.

Valuation — source: SEC EDGAR (first-party)
Price	$33.09
Market Cap	$1.97B
Price / Book	1.92
Price / Sales	19.86
FCF Yield	-35.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$54.03M
Net Margin	-764.0%
Revenue Growth (YoY)	48.0%
EPS Growth (YoY)	-160.0%
FCF Growth (YoY)	-3.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	10.21 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($194.69M)
Institutional Holders Tracked	10
Congressional Trades (recent)	3

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Brian Goff
Employees	486
Country	US
IPO Date	2013-07-24

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.